CCT239065
CCT239065 is an orally available, effective inhibitor of the mutant protein kinase V600EBRAF (RAF) with anti-tumor activity. CCT239065 inhibits downstream signaling of V600EBRAF in cancer cells, blocking DNA synthesis and suppressing proliferation.
For research use only. We do not sell to patients.
- CAS No.: 1163719-51-4
- Formula: C29H29N7O3S
- Molecular Weight:555.65
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All DNA/RNA Synthesis Isoforms
More
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| WM 266-4 | GI50 |
0.001 μM
Compound: 1t
|
Growth inhibition of human WM266.4 cells expressing BRAF V600E mutant after 5 days by SRB assay
Growth inhibition of human WM266.4 cells expressing BRAF V600E mutant after 5 days by SRB assay
|
[PMID: 20597484] |
Chemical Information
-
CAS No. 1163719-51-4
-
Molecular Weight 555.65
-
Formula C29H29N7O3S
-
SMILES
O=C1C=NC2=C(N1)N=CC=C2OC3=CC=C(C(SC)=C3)NC(NC4=CC(C(C)(C)C)=NN4C5=CC=C(C)C=C5)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Steven Whittaker, et al. A Novel, Selective, and Efficacious Nanomolar Pyridopyrazinone Inhibitor of V600EBRAF. Cancer Res. 2010 Oct 15;70(20):8036-44. [Content Brief]
[2]. James A McCubrey, et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget. 2012 Oct;3(10):1068-111. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)